 GSK PLC LSE:GSK, NYSE:GSK hailed as truly exceptional the results from a phase III clinical trial of its respiratory syncytial virus RSV vaccine in people over 60. RSV causes cold-like symptoms, which while mostly mild, can affect older adults more acutely, sometimes resulting in hospitalisation. 